Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04231877
Title Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Washington
Indications

B-cell lymphoma

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field